ID   ARRB2_MOUSE             Reviewed;         410 AA.
AC   Q91YI4; Q3TCM2; Q5F2D8; Q5F2E0;
DT   05-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   07-APR-2021, entry version 165.
DE   RecName: Full=Beta-arrestin-2;
DE   AltName: Full=Arrestin beta-2;
GN   Name=Arrb2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   STRAIN=C57BL/6J, and NOD;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=11588219; DOI=10.1126/science.1063866;
RA   Shenoy S.K., McDonald P.H., Kohout T.A., Lefkowitz R.J.;
RT   "Regulation of receptor fate by ubiquitination of activated beta 2-
RT   adrenergic receptor and beta-arrestin.";
RL   Science 294:1307-1313(2001).
RN   [5]
RP   SUBCELLULAR LOCATION, NUCLEOCYTOPLASMIC SHUTTLING, AND MUTAGENESIS OF
RP   LEU-395.
RX   PubMed=12167659; DOI=10.1074/jbc.m207552200;
RA   Scott M.G., Le Rouzic E., Perianin A., Pierotti V., Enslen H., Benichou S.,
RA   Marullo S., Benmerah A.;
RT   "Differential nucleocytoplasmic shuttling of beta-arrestins.
RT   Characterization of a leucine-rich nuclear export signal in beta-
RT   arrestin2.";
RL   J. Biol. Chem. 277:37693-37701(2002).
RN   [6]
RP   FUNCTION IN ENDOCYTOSIS OF LDLR, AND DISRUPTION PHENOTYPE.
RX   PubMed=12944399; DOI=10.1074/jbc.m309450200;
RA   Wu J.-H., Peppel K., Nelson C.D., Lin F.-T., Kohout T.A., Miller W.E.,
RA   Exum S.T., Freedman N.J.;
RT   "The adaptor protein beta-arrestin2 enhances endocytosis of the low density
RT   lipoprotein receptor.";
RL   J. Biol. Chem. 278:44238-44245(2003).
RN   [7]
RP   FUNCTION IN AKT1 SIGNALING, ASSOCIATION WITH PP2A, INTERACTION WITH AKT1;
RP   GSK3A AND GSK3B, AND DISRUPTION PHENOTYPE.
RX   PubMed=16051150; DOI=10.1016/j.cell.2005.05.012;
RA   Beaulieu J.-M., Sotnikova T.D., Marion S., Lefkowitz R.J.,
RA   Gainetdinov R.R., Caron M.G.;
RT   "An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic
RT   neurotransmission and behavior.";
RL   Cell 122:261-273(2005).
RN   [8]
RP   FUNCTION IN INTERNALIZATION OF ENG, AND FUNCTION IN TGF-BETA-MEDIATED ERK
RP   SIGNALING.
RX   PubMed=17540773; DOI=10.1074/jbc.m700176200;
RA   Lee N.Y., Blobe G.C.;
RT   "The interaction of endoglin with beta-arrestin2 regulates transforming
RT   growth factor-beta-mediated ERK activation and migration in endothelial
RT   cells.";
RL   J. Biol. Chem. 282:21507-21517(2007).
RN   [9]
RP   FUNCTION IN BETA-ADRENERGIC RECEPTOR REGULATION.
RX   PubMed=18337459; DOI=10.1096/fj.07-102459;
RA   Deshpande D.A., Theriot B.S., Penn R.B., Walker J.K.;
RT   "Beta-arrestins specifically constrain beta2-adrenergic receptor signaling
RT   and function in airway smooth muscle.";
RL   FASEB J. 22:2134-2141(2008).
RN   [10]
RP   INTERACTION WITH CHUK.
RX   PubMed=18194271; DOI=10.1111/j.1365-2567.2007.02781.x;
RA   Kizaki T., Izawa T., Sakurai T., Haga S., Taniguchi N., Tajiri H.,
RA   Watanabe K., Day N.K., Toba K., Ohno H.;
RT   "Beta2-adrenergic receptor regulates Toll-like receptor-4-induced nuclear
RT   factor-kappaB activation through beta-arrestin 2.";
RL   Immunology 124:348-356(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-48, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=18034455; DOI=10.1021/pr0701254;
RA   Ballif B.A., Carey G.R., Sunyaev S.R., Gygi S.P.;
RT   "Large-scale identification and evolution indexing of tyrosine
RT   phosphorylation sites from murine brain.";
RL   J. Proteome Res. 7:311-318(2008).
RN   [12]
RP   FUNCTION IN REGULATION OF INNATE IMMUNE RESPONSE, AND DISRUPTION PHENOTYPE.
RX   PubMed=18604210; DOI=10.1038/ni.1635;
RA   Yu M.-C., Su L.-L., Zou L., Liu Y., Wu N., Kong L., Zhuang Z.-H., Sun L.,
RA   Liu H.P., Hu J.-H., Li D., Strominger J.L., Zang J.-W., Pei G., Ge B.-X.;
RT   "An essential function for beta-arrestin 2 in the inhibitory signaling of
RT   natural killer cells.";
RL   Nat. Immunol. 9:898-907(2008).
RN   [13]
RP   FUNCTION IN INSULIN SIGNALING, INTERACTION WITH SRC; AKT1 AND INSR, AND
RP   DISRUPTION PHENOTYPE.
RX   PubMed=19122674; DOI=10.1038/nature07617;
RA   Luan B., Zhao J., Wu H., Duan B., Shu G., Wang X., Li D., Jia W., Kang J.,
RA   Pei G.;
RT   "Deficiency of a beta-arrestin-2 signal complex contributes to insulin
RT   resistance.";
RL   Nature 457:1146-1149(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [15]
RP   INTERACTION WITH FFAR4.
RX   PubMed=26873857; DOI=10.1124/mol.115.101949;
RA   Prihandoko R., Alvarez-Curto E., Hudson B.D., Butcher A.J., Ulven T.,
RA   Miller A.M., Tobin A.B., Milligan G.;
RT   "Distinct Phosphorylation Clusters Determine the Signaling Outcome of Free
RT   Fatty Acid Receptor 4/G Protein-Coupled Receptor 120.";
RL   Mol. Pharmacol. 89:505-520(2016).
CC   -!- FUNCTION: Functions in regulating agonist-mediated G-protein coupled
CC       receptor (GPCR) signaling by mediating both receptor desensitization
CC       and resensitization processes. During homologous desensitization, beta-
CC       arrestins bind to the GPRK-phosphorylated receptor and sterically
CC       preclude its coupling to the cognate G-protein; the binding appears to
CC       require additional receptor determinants exposed only in the active
CC       receptor conformation. The beta-arrestins target many receptors for
CC       internalization by acting as endocytic adapters (CLASPs, clathrin-
CC       associated sorting proteins) and recruiting the GPRCs to the adapter
CC       protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the
CC       extent of beta-arrestin involvement appears to vary significantly
CC       depending on the receptor, agonist and cell type. Internalized
CC       arrestin-receptor complexes traffic to intracellular endosomes, where
CC       they remain uncoupled from G-proteins. Two different modes of arrestin-
CC       mediated internalization occur. Class A receptors, like ADRB2, OPRM1,
CC       ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the
CC       plasma membrane and undergo rapid recycling. Class B receptors, like
CC       AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with
CC       arrestin and traffic with it to endosomal vesicles, presumably as
CC       desensitized receptors, for extended periods of time. Receptor
CC       resensitization then requires that receptor-bound arrestin is removed
CC       so that the receptor can be dephosphorylated and returned to the plasma
CC       membrane. Mediates endocytosis of CCR7 following ligation of CCL19 but
CC       not CCL21. Involved in internalization of P2RY1, P2RY4, P2RY6 and
CC       P2RY11 and ATP-stimulated internalization of P2RY2. Involved in
CC       phosphorylation-dependent internalization of OPRD1 and subsequent
CC       recycling or degradation. Involved in ubiquitination of IGF1R. Beta-
CC       arrestins function as multivalent adapter proteins that can switch the
CC       GPCR from a G-protein signaling mode that transmits short-lived signals
CC       from the plasma membrane via small molecule second messengers and ion
CC       channels to a beta-arrestin signaling mode that transmits a distinct
CC       set of signals that are initiated as the receptor internalizes and
CC       transits the intracellular compartment. Acts as signaling scaffold for
CC       MAPK pathways such as MAPK1/3 (ERK1/2) and MAPK10 (JNK3). ERK1/2 and
CC       JNK3 activated by the beta-arrestin scaffold are largely excluded from
CC       the nucleus and confined to cytoplasmic locations such as endocytic
CC       vesicles, also called beta-arrestin signalosomes. Acts as signaling
CC       scaffold for the AKT1 pathway. GPCRs for which the beta-arrestin-
CC       mediated signaling relies on both ARRB1 and ARRB2 (codependent
CC       regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-
CC       arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is
CC       inhibited by the other respective beta-arrestin form (reciprocal
CC       regulation). Increases ERK1/2 signaling in AGTR1- and AVPR2-mediated
CC       activation (reciprocal regulation). Involved in CCR7-mediated ERK1/2
CC       signaling involving ligand CCL19. Is involved in type-1A angiotensin II
CC       receptor/AGTR1-mediated ERK activity. Is involved in type-1A
CC       angiotensin II receptor/AGTR1-mediated MAPK10 activity. Is involved in
CC       dopamine-stimulated AKT1 activity in the striatum by disrupting the
CC       association of AKT1 with its negative regulator PP2A. Involved in
CC       AGTR1-mediated chemotaxis. Appears to function as signaling scaffold
CC       involved in regulation of MIP-1-beta-stimulated CCR5-dependent
CC       chemotaxis. Involved in attenuation of NF-kappa-B-dependent
CC       transcription in response to GPCR or cytokine stimulation by
CC       interacting with and stabilizing CHUK. Suppresses UV-induced NF-kappa-
CC       B-dependent activation by interacting with CHUK. The function is
CC       promoted by stimulation of ADRB2 and dephosphorylation of ARRB2.
CC       Involved in IL8-mediated granule release in neutrophils (By
CC       similarity). Involved in p53/TP53-mediated apoptosis by regulating MDM2
CC       and reducing the MDM2-mediated degradation of p53/TP53. May serve as
CC       nuclear messenger for GPCRs. Upon stimulation of OR1D2, may be involved
CC       in regulation of gene expression during the early processes of
CC       fertilization. Also involved in regulation of receptors other than
CC       GPCRs. Involved in endocytosis of TGFBR2 and TGFBR3 and down-regulates
CC       TGF-beta signaling such as NF-kappa-B activation. Involved in
CC       endocytosis of low-density lipoprotein receptor/LDLR. Involved in
CC       endocytosis of smoothened homolog/Smo, which also requires GRK2.
CC       Involved in endocytosis of SLC9A5. Involved in endocytosis of ENG and
CC       subsequent TGF-beta-mediated ERK activation and migration of epithelial
CC       cells. Involved in Toll-like receptor and IL-1 receptor signaling
CC       through the interaction with TRAF6 which prevents TRAF6
CC       autoubiquitination and oligomerization required for activation of NF-
CC       kappa-B and JUN. Involved in insulin resistance by acting as insulin-
CC       induced signaling scaffold for SRC, AKT1 and INSR. Involved in
CC       regulation of inhibitory signaling of natural killer cells by
CC       recruiting PTPN6 and PTPN11 to KIR2DL1. Involved in the internalization
CC       of the atypical chemokine receptor ACKR3 (By similarity). Acts as an
CC       adapter protein coupling FFAR4 receptor to specific downstream
CC       signaling pathways, as well as mediating receptor endocytosis. During
CC       the activation step of NLRP3 inflammasome, directly associates with
CC       NLRP3 leading to inhibition of proinflammatory cytokine release and
CC       inhibition of inflammation. {ECO:0000250, ECO:0000250|UniProtKB:P32121,
CC       ECO:0000269|PubMed:12944399, ECO:0000269|PubMed:16051150,
CC       ECO:0000269|PubMed:17540773, ECO:0000269|PubMed:18337459,
CC       ECO:0000269|PubMed:18604210, ECO:0000269|PubMed:19122674}.
CC   -!- SUBUNIT: Homooligomer; the self-association is mediated by InsP6-
CC       binding (Probable). Heterooligomer with ARRB1; the association is
CC       mediated by InsP6-binding. Interacts with ADRB2 AND CHRM2. Interacts
CC       with PDE4A. Interacts with PDE4D. Interacts with MAPK10, MAPK1 and
CC       MAPK3. Interacts with DRD2. Interacts with FSHR. Interacts with CLTC.
CC       Interacts with HTR2C. Interacts with CCR5. Interacts with CXCR4.
CC       Interacts with SRC. Interacts with DUSP16; the interaction is
CC       interrupted by stimulation of AGTR1 and activation of MAPK10. Interacts
CC       with CHUK; the interaction is enhanced stimulation of ADRB2. Interacts
CC       with RELA. Interacts with MDM2; the interaction is enhanced by
CC       activation of GPCRs. Interacts with SLC9A5. Interacts with TRAF6.
CC       Interacts with IGF1R. Interacts with ENG. Interacts with ARRB2.
CC       Interacts with KIR2DL1, KIR2DL3 and KIR2DL4. Interacts with LDLR.
CC       Interacts with AP2B1. Interacts with C5AR1. Interacts with RAF1.
CC       Interacts with MAP2K1. Interacts with MAPK1. Interacts with MAPK10; the
CC       interaction enhances MAPK10 activation by MAP3K5. Interacts with
CC       MAP2K4; the interaction is enhanced by presence of MAP3K5 and MAPK10.
CC       Interacts with MAP3K5. Interacts with AKT1. Interacts with IKBKB and
CC       MAP3K14. Interacts with SMO (activated). Interacts with GSK3A and
CC       GSK3B. Interacts with CXCR4; the interaction is dependent on C-terminal
CC       phosphorylation of CXCR4 and allows activation of MAPK1 and MAPK3.
CC       Interacts with GPR143. Interacts with HCK and CXCR1 (phosphorylated)
CC       (By similarity). Associates with protein phosphatase 2A (PP2A).
CC       Interacts with ACKR3 and ACKR4 (By similarity). Interacts with ARRDC1;
CC       the interaction is direct (By similarity). Interacts with GPR61, GPR62
CC       and GPR135 (By similarity). Interacts (via NACHT and LRR domains) with
CC       NLRP3; this interaction is direct and inducible by omega-3
CC       polyunsaturated fatty acids (PUFAs) (By similarity). Interacts with
CC       FFAR4 (via C-terminus); this interaction is stimulated by long-chain
CC       fatty acids (LCFAs) (PubMed:26873857). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P32121, ECO:0000269|PubMed:26873857,
CC       ECO:0000305}.
CC   -!- INTERACTION:
CC       Q91YI4; P58660: Card10; NbExp=7; IntAct=EBI-994161, EBI-8344379;
CC       Q91YI4; Q7TMA4: Ffar4; NbExp=4; IntAct=EBI-994161, EBI-2912413;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12167659}. Nucleus
CC       {ECO:0000269|PubMed:12167659}. Cell membrane
CC       {ECO:0000269|PubMed:12167659}. Membrane, clathrin-coated pit
CC       {ECO:0000250}. Cytoplasmic vesicle {ECO:0000250}. Note=Translocates to
CC       the plasma membrane and colocalizes with antagonist-stimulated GPCRs.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q91YI4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q91YI4-2; Sequence=VSP_020652;
CC   -!- TISSUE SPECIFICITY: Predominantly localized in neuronal tissues and in
CC       the spleen.
CC   -!- PTM: Phosphorylated at Thr-383 in the cytoplasm; probably
CC       dephosphorylated at the plasma membrane. The phosphorylation does not
CC       regulate internalization and recycling of ADRB2, interaction with
CC       clathrin or AP2B1 (By similarity). {ECO:0000250}.
CC   -!- PTM: The ubiquitination status appears to regulate the formation and
CC       trafficking of beta-arrestin-GPCR complexes and signaling.
CC       Ubiquitination appears to occur GPCR-specific. Ubiquitinated by MDM2;
CC       the ubiquitination is required for rapid internalization of ADRB2.
CC       Deubiquitinated by USP33; the deubiquitination leads to a dissociation
CC       of the beta-arrestin-GPCR complex. Stimulation of a class A GPCR, such
CC       as ADRB2, induces transient ubiquitination and subsequently promotes
CC       association with USP33. Stimulation of a class B GPCR promotes a
CC       sustained ubiquitination (By similarity). {ECO:0000250}.
CC   -!- PTM: Hydroxylation by PHD2 modulates the rate of internalization by
CC       slowing down recruitment to the plasma membrane and inhibiting
CC       subsequent co-internalization with class A receptors. {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Loss of beta-2 adrenergic receptor/ADRB2
CC       ubiquitination. Reduction of dopamine-dependent behaviors, loss of Akt1
CC       regulation by dopamine in the striatum and disruption of the dopamine-
CC       dependent interaction of Akt1 with its negative regulator, protein
CC       phosphatase 2A. Increased serum LDL-cholesterol levels upon high fat
CC       diet. Exacerbates insulin resistance. Elevated cytotoxicity of natural
CC       killer cells and lowered susceptibility to mouse cytomegalovirus
CC       infection. {ECO:0000269|PubMed:11588219, ECO:0000269|PubMed:12944399,
CC       ECO:0000269|PubMed:16051150, ECO:0000269|PubMed:18604210,
CC       ECO:0000269|PubMed:19122674}.
CC   -!- SIMILARITY: Belongs to the arrestin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK154874; BAE32894.1; -; mRNA.
DR   EMBL; AK159317; BAE34984.1; -; mRNA.
DR   EMBL; AK170647; BAE41934.1; -; mRNA.
DR   EMBL; AK170889; BAE42096.1; -; mRNA.
DR   EMBL; AL596096; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC016642; AAH16642.1; -; mRNA.
DR   CCDS; CCDS24946.1; -. [Q91YI4-1]
DR   CCDS; CCDS70226.1; -. [Q91YI4-2]
DR   RefSeq; NP_001258287.1; NM_001271358.1. [Q91YI4-2]
DR   RefSeq; NP_001258288.1; NM_001271359.1. [Q91YI4-2]
DR   RefSeq; NP_001258289.1; NM_001271360.1. [Q91YI4-1]
DR   RefSeq; NP_663404.1; NM_145429.5. [Q91YI4-1]
DR   SMR; Q91YI4; -.
DR   BioGRID; 229812; 45.
DR   CORUM; Q91YI4; -.
DR   DIP; DIP-36064N; -.
DR   ELM; Q91YI4; -.
DR   IntAct; Q91YI4; 34.
DR   STRING; 10090.ENSMUSP00000104208; -.
DR   iPTMnet; Q91YI4; -.
DR   PhosphoSitePlus; Q91YI4; -.
DR   SwissPalm; Q91YI4; -.
DR   EPD; Q91YI4; -.
DR   jPOST; Q91YI4; -.
DR   PaxDb; Q91YI4; -.
DR   PeptideAtlas; Q91YI4; -.
DR   PRIDE; Q91YI4; -.
DR   ProteomicsDB; 283247; -. [Q91YI4-1]
DR   ProteomicsDB; 283248; -. [Q91YI4-2]
DR   Antibodypedia; 23372; 361 antibodies.
DR   Ensembl; ENSMUST00000079056; ENSMUSP00000078065; ENSMUSG00000060216. [Q91YI4-2]
DR   Ensembl; ENSMUST00000102563; ENSMUSP00000099623; ENSMUSG00000060216. [Q91YI4-1]
DR   Ensembl; ENSMUST00000102564; ENSMUSP00000099624; ENSMUSG00000060216. [Q91YI4-1]
DR   Ensembl; ENSMUST00000108568; ENSMUSP00000104208; ENSMUSG00000060216. [Q91YI4-2]
DR   GeneID; 216869; -.
DR   KEGG; mmu:216869; -.
DR   UCSC; uc007jur.2; mouse. [Q91YI4-1]
DR   CTD; 409; -.
DR   MGI; MGI:99474; Arrb2.
DR   eggNOG; KOG3865; Eukaryota.
DR   GeneTree; ENSGT00950000182887; -.
DR   HOGENOM; CLU_033484_1_1_1; -.
DR   InParanoid; Q91YI4; -.
DR   OMA; APEINDP; -.
DR   PhylomeDB; Q91YI4; -.
DR   TreeFam; TF314260; -.
DR   Reactome; R-MMU-418555; G alpha (s) signalling events.
DR   Reactome; R-MMU-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; R-MMU-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-MMU-5635838; Activation of SMO.
DR   Reactome; R-MMU-5674135; MAP2K and MAPK activation.
DR   Reactome; R-MMU-5689880; Ub-specific processing proteases.
DR   Reactome; R-MMU-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-MMU-8856828; Clathrin-mediated endocytosis.
DR   BioGRID-ORCS; 216869; 2 hits in 53 CRISPR screens.
DR   ChiTaRS; Arrb2; mouse.
DR   PRO; PR:Q91YI4; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   RNAct; Q91YI4; protein.
DR   Bgee; ENSMUSG00000060216; Expressed in granulocyte and 275 other tissues.
DR   ExpressionAtlas; Q91YI4; baseline and differential.
DR   Genevisible; Q91YI4; MM.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISO:MGI.
DR   GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISO:MGI.
DR   GO; GO:0005829; C:cytosol; ISO:MGI.
DR   GO; GO:0043197; C:dendritic spine; ISO:MGI.
DR   GO; GO:0030139; C:endocytic vesicle; ISS:UniProtKB.
DR   GO; GO:0005768; C:endosome; ISO:MGI.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0014069; C:postsynaptic density; ISO:MGI.
DR   GO; GO:0045211; C:postsynaptic membrane; ISO:MGI.
DR   GO; GO:0071889; F:14-3-3 protein binding; ISO:MGI.
DR   GO; GO:0031691; F:alpha-1A adrenergic receptor binding; ISO:MGI.
DR   GO; GO:0031692; F:alpha-1B adrenergic receptor binding; ISO:MGI.
DR   GO; GO:0031701; F:angiotensin receptor binding; ISO:MGI.
DR   GO; GO:1990763; F:arrestin family protein binding; ISO:MGI.
DR   GO; GO:0031748; F:D1 dopamine receptor binding; ISO:MGI.
DR   GO; GO:0019899; F:enzyme binding; ISO:MGI.
DR   GO; GO:0031762; F:follicle-stimulating hormone receptor binding; ISO:MGI.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; ISO:MGI.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; ISO:MGI.
DR   GO; GO:0031859; F:platelet activating factor receptor binding; ISO:MGI.
DR   GO; GO:0019904; F:protein domain specific binding; ISO:MGI.
DR   GO; GO:0043422; F:protein kinase B binding; IPI:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; ISO:MGI.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:MGI.
DR   GO; GO:0031702; F:type 1 angiotensin receptor binding; ISO:MGI.
DR   GO; GO:0031826; F:type 2A serotonin receptor binding; ISO:MGI.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:MGI.
DR   GO; GO:0007628; P:adult walking behavior; IMP:UniProtKB.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0060326; P:cell chemotaxis; ISO:MGI.
DR   GO; GO:0002032; P:desensitization of G protein-coupled receptor signaling pathway by arrestin; ISO:MGI.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; ISO:MGI.
DR   GO; GO:0006897; P:endocytosis; ISO:MGI.
DR   GO; GO:0042699; P:follicle-stimulating hormone signaling pathway; ISO:MGI.
DR   GO; GO:0002031; P:G protein-coupled receptor internalization; ISO:MGI.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; ISO:MGI.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; ISO:MGI.
DR   GO; GO:0034260; P:negative regulation of GTPase activity; ISO:MGI.
DR   GO; GO:0032691; P:negative regulation of interleukin-1 beta production; IMP:UniProtKB.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IMP:UniProtKB.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IMP:UniProtKB.
DR   GO; GO:0045953; P:negative regulation of natural killer cell mediated cytotoxicity; ISO:MGI.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISO:MGI.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; ISO:MGI.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; ISO:MGI.
DR   GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; ISO:MGI.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; ISO:MGI.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IMP:UniProtKB.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; ISO:MGI.
DR   GO; GO:2000727; P:positive regulation of cardiac muscle cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; ISO:MGI.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISO:MGI.
DR   GO; GO:1904037; P:positive regulation of epithelial cell apoptotic process; ISO:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISO:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISO:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:MGI.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IC:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; ISS:UniProtKB.
DR   GO; GO:0032226; P:positive regulation of synaptic transmission, dopaminergic; IMP:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISO:MGI.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0016567; P:protein ubiquitination; ISO:MGI.
DR   GO; GO:0031623; P:receptor internalization; ISO:MGI.
DR   GO; GO:0008277; P:regulation of G protein-coupled receptor signaling pathway; IMP:MGI.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IDA:MGI.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISO:MGI.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISO:MGI.
DR   Gene3D; 2.60.40.640; -; 1.
DR   Gene3D; 2.60.40.840; -; 1.
DR   InterPro; IPR000698; Arrestin.
DR   InterPro; IPR011021; Arrestin-like_N.
DR   InterPro; IPR014752; Arrestin_C.
DR   InterPro; IPR011022; Arrestin_C-like.
DR   InterPro; IPR017864; Arrestin_CS.
DR   InterPro; IPR014753; Arrestin_N.
DR   InterPro; IPR014756; Ig_E-set.
DR   PANTHER; PTHR11792; PTHR11792; 1.
DR   Pfam; PF02752; Arrestin_C; 1.
DR   Pfam; PF00339; Arrestin_N; 1.
DR   PRINTS; PR00309; ARRESTIN.
DR   SMART; SM01017; Arrestin_C; 1.
DR   SUPFAM; SSF81296; SSF81296; 2.
DR   PROSITE; PS00295; ARRESTINS; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Coated pit; Cytoplasm;
KW   Cytoplasmic vesicle; Hydroxylation; Membrane; Nucleus; Phosphoprotein;
KW   Protein transport; Reference proteome; Signal transduction inhibitor;
KW   Transport; Ubl conjugation.
FT   CHAIN           1..410
FT                   /note="Beta-arrestin-2"
FT                   /id="PRO_0000205200"
FT   REGION          241..410
FT                   /note="Interaction with TRAF6"
FT                   /evidence="ECO:0000250"
FT   REGION          364..410
FT                   /note="Interaction with AP2B1"
FT                   /evidence="ECO:0000250"
FT   MOTIF           386..396
FT                   /note="[DE]-X(1,2)-F-X-X-[FL]-X-X-X-R motif"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         48
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18034455"
FT   MOD_RES         176
FT                   /note="Hydroxyproline; by PHD2"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         181
FT                   /note="Hydroxyproline; by PHD2"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         361
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P29067"
FT   MOD_RES         383
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P29067"
FT   VAR_SEQ         360
FT                   /note="Q -> QSAPIHPPLLCP (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16141072"
FT                   /id="VSP_020652"
FT   MUTAGEN         395
FT                   /note="L->A: Nuclear localization. Causes nuclear
FT                   relocalization of MAPK10."
FT                   /evidence="ECO:0000269|PubMed:12167659"
FT   CONFLICT        11
FT                   /note="K -> R (in Ref. 1; BAE41934)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        59
FT                   /note="T -> N (in Ref. 1; BAE41934)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        75
FT                   /note="S -> Y (in Ref. 1; BAE41934)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   410 AA;  46314 MW;  0DFA73A1C532AE03 CRC64;
     MGEKPGTRVF KKSSPNCKLT VYLGKRDFVD HLDKVDPVDG VVLVDPDYLK DRKVFVTLTC
     AFRYGREDLD VLGLSFRKDL FIATYQAFPP MPNPPRPPTR LQDRLLKKLG QHAHPFFFTI
     PQNLPCSVTL QPGPEDTGKA CGVDFEIRAF CAKSIEEKSH KRNSVRLIIR KVQFAPETPG
     PQPSAETTRH FLMSDRRSLH LEASLDKELY YHGEPLNVNV HVTNNSAKTV KKIRVSVRQY
     ADICLFSTAQ YKCPVAQLEQ DDQVSPSSTF CKVYTITPLL SDNREKRGLA LDGQLKHEDT
     NLASSTIVKE GANKEVLGIL VSYRVKVKLV VSRGGDVSVE LPFVLMHPKP HDHITLPRPQ
     SAPRETDVPV DTNLIEFDTN YATDDDIVFE DFARLRLKGM KDDDCDDQFC
//
